Cantor Fitzgerald Reaffirms “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They presently have a $2.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 25.79% from the company’s previous close. A number […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They presently have a $2.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 25.79% from the company’s previous close. A number […]
